Novo's Victoza REMS Settlement Opens Another Legal Door For Off-Label Promotion Cases
Executive Summary
US government alleged sales reps gave information to physicians to create a false or misleading impression that Victoza's boxed warning and REMS messages about medullary thyroid cancer were 'erroneous, irrelevant or unimportant.' Novo's $59m settlement includes resolution of whistleblower lawsuits alleging off-label marketing.
You may also be interested in...
US Enforcement 2019: Compounding, Opioids Top Priorities But Beware Of REMS Violations, Too
Drug manufacturer reimbursement support services also are garnering a growing amount of enforcement attention, and misleading promotion - whether on- or off-label - remains on the radar of government investigators.
The Benefits Of A Corporate Integrity Agreement: An Industry Perspective
Novo exec says CIAs can help spur culture change to improve sales rep compliance; cooperation can also help avoid corporate integrity agreements in future settlements.
Gilead Asks Supreme Court To Restrict False Claims Act Cases
Complaints should not be allowed to go forward if government knew of regulatory infraction but continued to pay for drug, Gilead argues, asking US high court to 'finish task' of its Escobar ruling.